The Molecular Medicine (Small Molecule Science) Platform is a fusion of medicinal chemistry, natural products chemistry, Traditional Chinese Medicine and pharmaceutical analysis. While each of these areas has its own identity and interests, the platform concept recognizes that there are many reasons for overlap between the areas, and these overlapping interests represent opportunities for collaborative research, leveraging the strengths of each discipline to build a discovery program that is greater than the sum of its parts. Modern research is inherently collaborative, so it is essential that we create a research environment that stimulates collaboration among a variety of scientists, allowing our students to learn how best to leverage the skills and knowledge of their colleagues and teachers to help solve their own research problems.
Nature is a rich source of novel molecules possessing complex biological activities. Most drugs used in Western medicine are either naturally occurring or are based on a natural product. The natural product chemist typically isolates interesting molecules having a biological activity and then identifies their chemical structure using a variety of spectroscopic and chemical methods. The medicinal chemist may then take such a lead structure, and synthesize it and related compounds to define the relationship between biological activity and structural features of the molecule. This structure-activity relationship (SAR) can be further refined via modular or combinatorial synthesis of libraries of closely related compounds, eventually leading to a drug candidate compound. The integration of Traditional Chinese Medicine into what could be described as a Western drug discovery program is an interesting and exciting opportunity. Most of the world’s population relies on some form of traditional medicine for their healthcare needs. While there is ample evidence that many traditional medical practices are effective in treating diseases, many in the West still consider them to be primitive and inferior to Western “modern” medicine. This misperception stems from the fact that science simply does not understand how or why traditional medicines work. Using the tools of natural products chemistry and modern analytical chemistry to study TCM will help us to understand the molecular basis of these useful and effective treatments. The Molecular Medicine Platform is a fusion of the various chemical disciplines involved in pharmaceutical research and development. In order to be a real drug discovery program, we rely on collaborations with the other, more biologically or biochemically focused platforms to develop and explore the pharmacologic targets that make chemistry relevant to treating disease.
The research in the Bureik group encompasses two primary areas:
1) The study of human drug metabolizing enzymes and their use for organic synthesis.
A major goal in this project involves systematic testing of all variants of drug metabolizing cytochrome P450 enzymes (CYPs or P450s) and UDP glycosyltransferases (UGTs) identified in Chinese patients. This is expected to aid doctors in choosing the correct dosage for patients.
2) Investigation of human CYP4Z1 and exploitation of its activity for the treatment of breast cancer.
In this project, we have successfully identified CYP4Z1 to catalyze fatty acid in-chain hydroxylase and also ether cleavage. A primary aim is to search for compounds that can act as CYP4Z1-activated prodrugs and have potential for treatment of breast cancer.
Recently published work:
In cooperation with the group of Prof. Gerhard Wolber (Free University Berlin, Germany) we recently published a homology model of a UGT1A5 variant (UGT1A5*8) which shows that the cofactor UDP-GA is placed in a much more favorable geometry in UGT1A5*8 as compared to the wild-type, thus explaining its increased catalytical activity (Yang et al., 2018):
(A) Structural homology model for UGT1A5*8 with bound cofactor Uridine-diphosphoglucoronic acid (UDP-GA). The secondary structure ribbon is shown in grey. Helix Q is highlighted in blue. The cofactor (colored turquois) is situated in the catalytic cleft between the N-terminal (left) and C-terminal (right) domains. (B) Superposition of C-terminal domains of the UGT2B7 crystal structure (yellow) and UGT1A5*8 homology model (grey) with a root-mean square root of 2. 1 Å. (C) Cofactor protein interaction diagram for UGT1A5 and UDP-GA. The glucuronic acid moiety of UDP-GA is hold in place by electrostatic interaction with Arg174 and hydrogen bonding to Ser376 and Asp397. The uridine-diphosphate moiety forms hydrogen bonds to Ser307, Leu308, His373, His377 and Gly378. Blue double-headed arrow represents electrostatic interaction. Red arrows represent hydrogen bond acceptance and green arrow hydrogen bond donation.
The research of the Chen group concerns isolation, identification, bioactivity, and mechanism of constituents from natural resources. In particular, the group focuses on functional mechanism and structure-activity relationships of macromolecules (polysaccharides and proteins) as well as small biomolecules. Methods are being developed in the group to quantify bioactivity of polysaccharides and small biomolecules from Traditional Chinese Medicine and natural resources. Additionally, the group investigates functional food and new medicine from natural sources.
Her research would be helpful to the investigation and utilization of natural resources. She has been the Primary Investigator (PI) in 15 projects such as the funds from National Natural Science Foundation of China (NSFC), National High Technology Research and Development Program ("863"Program) of China, Project of National Key Technology Research and Development Program for The 12th Five-year Plan, National Program on Key Basic Research Project (973 Program). More than 100 research papers of Dr. Haixia Chen have been published, and 73 of the papers are published on SCI/SCIE journals with Haixia Chen being the first author or correspondence author. She has participated in 8 published books. 35 Chinese patents have been applied and 17 of them were authorized. Her papers on the study of bioactive polysaccharides have been cited by many researchers around the world and the citation frequency reached 2200 times in SCI database with H index of 25. One of her paper has been cited more than 225 times at the end of April 2019. She has been the editorial board member of some journals such as EC Pharmacology and Toxicology, Journal of Food Safety & Quality, Pharmarceutical Journal of Chinese People’s Liberationl Armay. She has also been the reviewer of NSFC, MOST and MOE and many international journals and Chinese journals such as Frontiers in Pharmacology, Food Chemistry, Carbohydrate Polymers, International Journal of Biological Macromolecules, Food research international, Journal of Agricultural and Food Chemistry etc.
The research of Prof. Chen's group is focused on synthesis of biomaterials and development of modern separation and analysis technology. In particular, efforts include a) Development of mixed-mode chromatography stationary phases according to the structure of analytes. b) Design novel chiral stationary phases to establish “single-column detection technology” to improve the quality control efficiency of chiral drugs, and investigate the chiral separation mechanism by molecular simulation and chiral nuclear magnetic resonance. c) Exploitation of magnetic separation technology in the purification of biological samples. Additionally, efforts are extended towards control the morphology and pore structure of silica microspheres, and to optimize HPLC and LC-MS separation and identification methods for complex samples.
Our research is focused on developing and implementing proteomic strategies to gain new insights into the molecular mechanisms of diseases, especially cancer. The topics we are interested about are listed below.
1) To decipher the interactions between biological macromolecules, such as protein-protein interactions and long non-coding RNA (lncRNA)-protein interactions, by combing affinity purification, biological mass spectrometric analysis and bioinformatics, and also to understand their implications in cancer.
2) Systematic and comprehensive molecular profiling of tumor by multi-omics, integrating data from genetics, transcriptomics, proteomics, metabolomics, etc.
3) Single cell protein analysis. We employ a state-of-the-art technology called mass cytometry to analyze protein expressions in single cells. Multiplex analytical panels are designed to achieve precise sub-clustering of immune cells in the tumor microenvironment and to understand tumor heterogenesis.
Research in the Clark group focuses on microbial natural products as applied to drug discovery, metabolomics, and chemical ecology. Microbes have long been a source of potent antimicrobial and anticancer agents, and we have a particular interest in marine and extremophilic microbes as a source of new drug leads. We also investigate chemical ecology: what role the metabolites serve for the microbe itself, and how are they involved in the interaction of microbes with other organisms. The group uses molecular networking and multivariate statistical techniques in all of these research avenues in order to classify samples, identify active components, and elucidate the interactions of molecules and organisms. While microbes are the primary focus of the group we also have experience working with plants and marine organisms, if there are particularly interesting ecological questions to be addressed in these areas.
The research area of the Du group involves investigation of hypervalent iodine (III) – mediated transformations, including oxidative coupling, rearrangement, cascade reactions, and asymmetric reactions. Additionally, the group develops metal-free methodology for the constructionof heterocyclic compounds and pharmaceutical agents.
The research of the Gao group encompasses three main areas, including 1) Production of active constituents by biotechnology in medicinal plants, b) Development of functional products from Traditional Chinese Medicine and natural products, and c) Development of new drugs from Traditional Chinese Medicine and natural products.
Design and synthesis of novel Cholera Toxin inhibitor based on the rim-differentiated C5-symmetrical Tiara-Pillar[5]arene scaffold.
Identification and characterization of new enzymes and new metabolic pathways in nature using a combination of bioinformatics, genetic, biochemical and biophysical methods.
Wang’s research addresses production of traditional Chinese medicine (TCM) active compounds through biotechnology. 1. Analysis of TCM active compounds biosynthesis pathway. 2. Studies on TCM active compounds metabolism regulation. 3. Large scale tissue culture of TCM active compounds.
The research in the group of Li involves investigations into Traditional Chinese Medicines (TCM). The emphasis is on the genetic relationship among medicinal plants based on macromolecules, such as starch and polysaccharides, and the development of process techniques for herbal materials. Additionally, the group is involved in the development of functional foods from TCM and their effective constituents. Functional products with throat clearing, hypoglycemic, hypolipidemic and aperient bowel functions have been developed.
Li’s research addresses development and application of electrophoresis techniques,heterogeneous catalysis and applications, chiral separation and applications, sample preparation and applications, and high throughput drug screening based on hollow fiber member system development.
The research in the group of Srinivasan encompasses two main areas, 1) Developing new reaction methodologies: The research topics under this area include bioorthogonal reactions, late-stage modification of advanced chemical entities, C-H activation, and high-throughput amenable synthesis – aiming at advancing the way organic molecules are made for drug discovery and chemical biology applications. 2) Inhibitor discovery based on fragment-based approaches: Design and synthesis of ‘unconventional’ fragments with rich structural diversity. These fragments will be used as a starting point towards novel inhibitors for unexplored biological targets such as the AurB-INCENP interaction.
The research in the group of Su encompasses three main areas, including a) Isolation and identification of bioactive natural compounds from medicinal plants, b) Quality control of traditional chinese medicines, 3) Research & development of new medicines of natural origin
Developing innovative synthetic methodologies in photo-catalysis and earth-abundant
metal catalysis, with particular interest in constructing organo-fluorine compounds
and related drug modifications.
The research in the group of Wang encompasses four main areas, including 1) Functional polymeric materials (biodegradable polymeric materials, smart polymeric materials such as thermo-sensitive and pH sensitive polymers, dendrimers etc.), 2) Nanotechnology for solubility improvement of water-insoluble drugs, 3) Targeted and controlled drug release systems, and 4) Self-assembled nanostructures for controlled drug release.
The research in the group of Wang involves the design, synthesis, and biological activity evaluation of new compounds, with focus on industrialization of generic drugs, intermediates, and fine chemicals. Specific areas include 1) Design and synthesis of the Rho kinase inhibitor, 2) Design and synthesis of the PDE4 inhibitor, and 3) Design and synthesis of antihistamine drugs
To support the projects of the research groups in the SPST by offering a state-of-the-art X-ray crystallography facility.
To contribute to the study of diffuse scattering and defect structure simulation by developing new and improving existing methods.
To understand the structure of crystalline materials and the relationships between the structure and properties of these materials.
The research in the group of Zhang is encompassed in the areas of chiral separation and proteomics analysis.
研究方向为药理毒理学，主持国自然面上项目、973计划子课题、天津市科委项目等，近5年作为唯一通讯或最后主通讯以天津大学为第一单位在《Pharmacological Reviews》杂志(IF:18，年均发文量28篇)、《Hepatology》（IF:15, 2篇）、《Nature Communications》(IF:14)、《Journal of Experimental and Clinical Cancer Research》(IF:12)等领域内顶刊发表多篇SCI论文。担任美国毒理学会官方杂志《Toxicological Sciences》副主编、美国生物化学和分子生物学会杂志《Journal of Lipid Research》编委、国内杂志《Medicine Advances》编委等。
The research interests include 1) MS-based multi-omics studies of clinical tissues (PTC) – biomarker / target screening for diagnosis and drug discovery; 2) Mass spectrometry methodology in pharmaceutical analysis; 3) combinatorial studies of non-covalent interactions in gas-phase and in solution; 4) mechanistic studies of OM-mediated homogenous catalytic reactions.
medical chemistry，medical synthetic chemistry, organic chemistry, organic reaction mechanism research
药物化学，药物合成化学，有机化学，有机反应机理研究
for detail information please see our group page：
https://www.x-mol.com/groups/chunzhang
1. Study the binding site and binding mechanism of stroke new drugs with rat plasma protein by using mass spectrometry and proteomics technology
2. Study the mass balance, pharmacokinetics, and metabolic pathways of innovative drugs in rats and humans by using radioactive labeling technology
3. Study the effects of orphan metabolic enzymes-CYP3A43 on drug metabolism, including CYP3A family enzymes, CYP3A43 mutants, and UGT enzymes on the metabolism of antipsychotic drugs
The Molecular Medicine (Small Molecule Science) Platform is a fusion of medicinal chemistry, natural products chemistry, Traditional Chinese Medicine and pharmaceutical analysis. While each of these areas has its own identity and interests, the platform concept recognizes that there are many reasons for overlap between the areas, and these overlapping interests represent opportunities for collaborative research, leveraging the strengths of each discipline to build a discovery program that is greater than the sum of its parts. Modern research is inherently collaborative, so it is essential that we create a research environment that stimulates collaboration among a variety of scientists, allowing our students to learn how best to leverage the skills and knowledge of their colleagues and teachers to help solve their own research problems.
Nature is a rich source of novel molecules possessing complex biological activities. Most drugs used in Western medicine are either naturally occurring or are based on a natural product. The natural product chemist typically isolates interesting molecules having a biological activity and then identifies their chemical structure using a variety of spectroscopic and chemical methods. The medicinal chemist may then take such a lead structure, and synthesize it and related compounds to define the relationship between biological activity and structural features of the molecule. This structure-activity relationship (SAR) can be further refined via modular or combinatorial synthesis of libraries of closely related compounds, eventually leading to a drug candidate compound. The integration of Traditional Chinese Medicine into what could be described as a Western drug discovery program is an interesting and exciting opportunity. Most of the world’s population relies on some form of traditional medicine for their healthcare needs. While there is ample evidence that many traditional medical practices are effective in treating diseases, many in the West still consider them to be primitive and inferior to Western “modern” medicine. This misperception stems from the fact that science simply does not understand how or why traditional medicines work. Using the tools of natural products chemistry and modern analytical chemistry to study TCM will help us to understand the molecular basis of these useful and effective treatments. The Molecular Medicine Platform is a fusion of the various chemical disciplines involved in pharmaceutical research and development. In order to be a real drug discovery program, we rely on collaborations with the other, more biologically or biochemically focused platforms to develop and explore the pharmacologic targets that make chemistry relevant to treating disease.
The research in the Bureik group encompasses two primary areas:
1) The study of human drug metabolizing enzymes and their use for organic synthesis.
A major goal in this project involves systematic testing of all variants of drug metabolizing cytochrome P450 enzymes (CYPs or P450s) and UDP glycosyltransferases (UGTs) identified in Chinese patients. This is expected to aid doctors in choosing the correct dosage for patients.
2) Investigation of human CYP4Z1 and exploitation of its activity for the treatment of breast cancer.
In this project, we have successfully identified CYP4Z1 to catalyze fatty acid in-chain hydroxylase and also ether cleavage. A primary aim is to search for compounds that can act as CYP4Z1-activated prodrugs and have potential for treatment of breast cancer.
Recently published work:
In cooperation with the group of Prof. Gerhard Wolber (Free University Berlin, Germany) we recently published a homology model of a UGT1A5 variant (UGT1A5*8) which shows that the cofactor UDP-GA is placed in a much more favorable geometry in UGT1A5*8 as compared to the wild-type, thus explaining its increased catalytical activity (Yang et al., 2018):
(A) Structural homology model for UGT1A5*8 with bound cofactor Uridine-diphosphoglucoronic acid (UDP-GA). The secondary structure ribbon is shown in grey. Helix Q is highlighted in blue. The cofactor (colored turquois) is situated in the catalytic cleft between the N-terminal (left) and C-terminal (right) domains. (B) Superposition of C-terminal domains of the UGT2B7 crystal structure (yellow) and UGT1A5*8 homology model (grey) with a root-mean square root of 2. 1 Å. (C) Cofactor protein interaction diagram for UGT1A5 and UDP-GA. The glucuronic acid moiety of UDP-GA is hold in place by electrostatic interaction with Arg174 and hydrogen bonding to Ser376 and Asp397. The uridine-diphosphate moiety forms hydrogen bonds to Ser307, Leu308, His373, His377 and Gly378. Blue double-headed arrow represents electrostatic interaction. Red arrows represent hydrogen bond acceptance and green arrow hydrogen bond donation.
The research of the Chen group concerns isolation, identification, bioactivity, and mechanism of constituents from natural resources. In particular, the group focuses on functional mechanism and structure-activity relationships of macromolecules (polysaccharides and proteins) as well as small biomolecules. Methods are being developed in the group to quantify bioactivity of polysaccharides and small biomolecules from Traditional Chinese Medicine and natural resources. Additionally, the group investigates functional food and new medicine from natural sources.
Her research would be helpful to the investigation and utilization of natural resources. She has been the Primary Investigator (PI) in 15 projects such as the funds from National Natural Science Foundation of China (NSFC), National High Technology Research and Development Program ("863"Program) of China, Project of National Key Technology Research and Development Program for The 12th Five-year Plan, National Program on Key Basic Research Project (973 Program). More than 100 research papers of Dr. Haixia Chen have been published, and 73 of the papers are published on SCI/SCIE journals with Haixia Chen being the first author or correspondence author. She has participated in 8 published books. 35 Chinese patents have been applied and 17 of them were authorized. Her papers on the study of bioactive polysaccharides have been cited by many researchers around the world and the citation frequency reached 2200 times in SCI database with H index of 25. One of her paper has been cited more than 225 times at the end of April 2019. She has been the editorial board member of some journals such as EC Pharmacology and Toxicology, Journal of Food Safety & Quality, Pharmarceutical Journal of Chinese People’s Liberationl Armay. She has also been the reviewer of NSFC, MOST and MOE and many international journals and Chinese journals such as Frontiers in Pharmacology, Food Chemistry, Carbohydrate Polymers, International Journal of Biological Macromolecules, Food research international, Journal of Agricultural and Food Chemistry etc.
The research of Prof. Chen's group is focused on synthesis of biomaterials and development of modern separation and analysis technology. In particular, efforts include a) Development of mixed-mode chromatography stationary phases according to the structure of analytes. b) Design novel chiral stationary phases to establish “single-column detection technology” to improve the quality control efficiency of chiral drugs, and investigate the chiral separation mechanism by molecular simulation and chiral nuclear magnetic resonance. c) Exploitation of magnetic separation technology in the purification of biological samples. Additionally, efforts are extended towards control the morphology and pore structure of silica microspheres, and to optimize HPLC and LC-MS separation and identification methods for complex samples.
Our research is focused on developing and implementing proteomic strategies to gain new insights into the molecular mechanisms of diseases, especially cancer. The topics we are interested about are listed below.
1) To decipher the interactions between biological macromolecules, such as protein-protein interactions and long non-coding RNA (lncRNA)-protein interactions, by combing affinity purification, biological mass spectrometric analysis and bioinformatics, and also to understand their implications in cancer.
2) Systematic and comprehensive molecular profiling of tumor by multi-omics, integrating data from genetics, transcriptomics, proteomics, metabolomics, etc.
3) Single cell protein analysis. We employ a state-of-the-art technology called mass cytometry to analyze protein expressions in single cells. Multiplex analytical panels are designed to achieve precise sub-clustering of immune cells in the tumor microenvironment and to understand tumor heterogenesis.
Research in the Clark group focuses on microbial natural products as applied to drug discovery, metabolomics, and chemical ecology. Microbes have long been a source of potent antimicrobial and anticancer agents, and we have a particular interest in marine and extremophilic microbes as a source of new drug leads. We also investigate chemical ecology: what role the metabolites serve for the microbe itself, and how are they involved in the interaction of microbes with other organisms. The group uses molecular networking and multivariate statistical techniques in all of these research avenues in order to classify samples, identify active components, and elucidate the interactions of molecules and organisms. While microbes are the primary focus of the group we also have experience working with plants and marine organisms, if there are particularly interesting ecological questions to be addressed in these areas.
The research area of the Du group involves investigation of hypervalent iodine (III) – mediated transformations, including oxidative coupling, rearrangement, cascade reactions, and asymmetric reactions. Additionally, the group develops metal-free methodology for the constructionof heterocyclic compounds and pharmaceutical agents.
The research of the Gao group encompasses three main areas, including 1) Production of active constituents by biotechnology in medicinal plants, b) Development of functional products from Traditional Chinese Medicine and natural products, and c) Development of new drugs from Traditional Chinese Medicine and natural products.
Design and synthesis of novel Cholera Toxin inhibitor based on the rim-differentiated C5-symmetrical Tiara-Pillar[5]arene scaffold.
Identification and characterization of new enzymes and new metabolic pathways in nature using a combination of bioinformatics, genetic, biochemical and biophysical methods.
Wang’s research addresses production of traditional Chinese medicine (TCM) active compounds through biotechnology. 1. Analysis of TCM active compounds biosynthesis pathway. 2. Studies on TCM active compounds metabolism regulation. 3. Large scale tissue culture of TCM active compounds.
The research in the group of Li involves investigations into Traditional Chinese Medicines (TCM). The emphasis is on the genetic relationship among medicinal plants based on macromolecules, such as starch and polysaccharides, and the development of process techniques for herbal materials. Additionally, the group is involved in the development of functional foods from TCM and their effective constituents. Functional products with throat clearing, hypoglycemic, hypolipidemic and aperient bowel functions have been developed.
Li’s research addresses development and application of electrophoresis techniques,heterogeneous catalysis and applications, chiral separation and applications, sample preparation and applications, and high throughput drug screening based on hollow fiber member system development.
The research in the group of Srinivasan encompasses two main areas, 1) Developing new reaction methodologies: The research topics under this area include bioorthogonal reactions, late-stage modification of advanced chemical entities, C-H activation, and high-throughput amenable synthesis – aiming at advancing the way organic molecules are made for drug discovery and chemical biology applications. 2) Inhibitor discovery based on fragment-based approaches: Design and synthesis of ‘unconventional’ fragments with rich structural diversity. These fragments will be used as a starting point towards novel inhibitors for unexplored biological targets such as the AurB-INCENP interaction.
The research in the group of Su encompasses three main areas, including a) Isolation and identification of bioactive natural compounds from medicinal plants, b) Quality control of traditional chinese medicines, 3) Research & development of new medicines of natural origin
Developing innovative synthetic methodologies in photo-catalysis and earth-abundant
metal catalysis, with particular interest in constructing organo-fluorine compounds
and related drug modifications.
The research in the group of Wang encompasses four main areas, including 1) Functional polymeric materials (biodegradable polymeric materials, smart polymeric materials such as thermo-sensitive and pH sensitive polymers, dendrimers etc.), 2) Nanotechnology for solubility improvement of water-insoluble drugs, 3) Targeted and controlled drug release systems, and 4) Self-assembled nanostructures for controlled drug release.
The research in the group of Wang involves the design, synthesis, and biological activity evaluation of new compounds, with focus on industrialization of generic drugs, intermediates, and fine chemicals. Specific areas include 1) Design and synthesis of the Rho kinase inhibitor, 2) Design and synthesis of the PDE4 inhibitor, and 3) Design and synthesis of antihistamine drugs
To support the projects of the research groups in the SPST by offering a state-of-the-art X-ray crystallography facility.
To contribute to the study of diffuse scattering and defect structure simulation by developing new and improving existing methods.
To understand the structure of crystalline materials and the relationships between the structure and properties of these materials.
The research in the group of Zhang is encompassed in the areas of chiral separation and proteomics analysis.
研究方向为药理毒理学，主持国自然面上项目、973计划子课题、天津市科委项目等，近5年作为唯一通讯或最后主通讯以天津大学为第一单位在《Pharmacological Reviews》杂志(IF:18，年均发文量28篇)、《Hepatology》（IF:15, 2篇）、《Nature Communications》(IF:14)、《Journal of Experimental and Clinical Cancer Research》(IF:12)等领域内顶刊发表多篇SCI论文。担任美国毒理学会官方杂志《Toxicological Sciences》副主编、美国生物化学和分子生物学会杂志《Journal of Lipid Research》编委、国内杂志《Medicine Advances》编委等。
The research interests include 1) MS-based multi-omics studies of clinical tissues (PTC) – biomarker / target screening for diagnosis and drug discovery; 2) Mass spectrometry methodology in pharmaceutical analysis; 3) combinatorial studies of non-covalent interactions in gas-phase and in solution; 4) mechanistic studies of OM-mediated homogenous catalytic reactions.
medical chemistry，medical synthetic chemistry, organic chemistry, organic reaction mechanism research
药物化学，药物合成化学，有机化学，有机反应机理研究
for detail information please see our group page：
https://www.x-mol.com/groups/chunzhang
1. Study the binding site and binding mechanism of stroke new drugs with rat plasma protein by using mass spectrometry and proteomics technology
2. Study the mass balance, pharmacokinetics, and metabolic pathways of innovative drugs in rats and humans by using radioactive labeling technology
3. Study the effects of orphan metabolic enzymes-CYP3A43 on drug metabolism, including CYP3A family enzymes, CYP3A43 mutants, and UGT enzymes on the metabolism of antipsychotic drugs
